



World Health
Organization

INTERIM GUIDELINES



UPDATED RECOMMENDATIONS ON FIRST-LINE AND SECOND-LINE ANTIRETROVIRAL REGIMENS AND POST-EXPOSURE PROPHYLAXIS AND RECOMMENDATIONS ON EARLY INFANT DIAGNOSIS OF HIV

SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES
ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING
AND PREVENTING HIV INFECTION

DECEMBER 2018

HIV TREATMENT

**UPDATED RECOMMENDATIONS ON
FIRST-LINE AND SECOND-LINE
ANTIRETROVIRAL REGIMENS AND
POST-EXPOSURE PROPHYLAXIS
AND RECOMMENDATIONS ON EARLY
INFANT DIAGNOSIS OF HIV:
INTERIM GUIDELINES**

**SUPPLEMENT TO THE 2016 CONSOLIDATED GUIDELINES
ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING
AND PREVENTING HIV INFECTION**

DECEMBER 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.51). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.



CONTENTS

| | |
|---|-------------|
| Acknowledgements | vi |
| Summary of key terms | viii |
| Abbreviations and acronyms | ix |
| Executive summary | x |
| 1. Objectives and target audience of the guidelines | 13 |
| 1.1 Objectives | 13 |
| 1.2 Target audience | 13 |
| 1.3 Guiding principles | 13 |
| 2. ARV drug regimens for people initiating ART | 14 |
| 2.1 Background | 15 |
| 2.2 Supporting evidence | 16 |
| 2.3 Rationale for the recommendation | 22 |
| 2.4 Clinical and implementation considerations | 26 |
| 2.5 Research gaps | 30 |
| 3. Second-line ARV drug regimens | 31 |
| 3.1 Background | 31 |
| 3.2 Supporting evidence | 32 |
| 3.3 Rationale for the recommendation | 34 |
| 3.4 Research gaps | 36 |
| 4. What to use in HIV post-exposure prophylaxis | 37 |
| 4.1 Background | 37 |
| 4.2 Supporting evidence | 38 |
| 4.3 Implementation considerations | 39 |
| 4.4 Research gaps | 39 |
| 5. Early infant diagnosis | 40 |
| 5.1 Background | 40 |
| 5.2 Supporting evidence | 40 |
| 5.3 Rationale for the recommendation | 41 |
| 5.4 Implementation considerations | 43 |
| 5.5 Research gaps | 43 |
| 6. Plans for updating, dissemination and evaluation | 44 |
| References | 45 |
| Annexes | 52 |
| Annex 1. Methods for developing the guidelines | 53 |
| Annex 2. Drug toxicity and drug–drug interactions of ARV drugs | 57 |
| Annex 3. Dosages of ARV drugs | 61 |
| Annex 4. Standard operating procedure for early infant diagnosis testing | 76 |
| Annex 5. Revised simplified early infant diagnosis algorithm | 77 |

WEB ANNEXES

<http://www.who.int/hiv/pub/guidelines/ARV2018update/en/>

Web Annex A

Declaration of interests of guideline development group and external review group

WHO/CDS/HIV/18.24

Web Annex B.

Systematic literature review and network meta-analysis assessing first-line ART treatments

WHO/CDS/HIV/18.25

Web Annex C.

Report on the safety of dolutegravir in pregnancy and breast feeding

WHO/CDS/HIV/18.26

Web Annex D.

Surveys of values and preferences

WHO/CDS/HIV/18.27

Web Annex E.

Recommendations for use of hormonal contraception for women living with HIV using antiretroviral therapy

WHO/CDS/HIV/18.28

Web Annex F.

Systematic review of which ART regimen to switch to when failing first-line treatment

WHO/CDS/HIV/18.29

Web Annex G.

Systematic review of the safety and efficacy of antiretroviral drugs for post-exposure prophylaxis

WHO/CDS/HIV/18.30

Web Annex H.

Indeterminate results during HIV early infant diagnosis testing: a meta-analysis and review of the literature

WHO/CDS/HIV/18.31

Web Annex I.

Report on the cost-effectiveness of implementing an indeterminate range for early infant diagnosis of HIV

WHO/CDS/HIV/18.32

Web Annex J.

Table of drug interactions

WHO/CDS/HIV/18.33

ACKNOWLEDGEMENTS

Guideline Development Group

Co-chairs: Elaine Abrams (ICAP at Columbia University, USA) and Serge Eholie (Treichville University Teaching Hospital, Côte d'Ivoire)

Methodologist: Nancy Santesso (GRADE methodologist, McMaster University, Canada)

Florence Anam (ICW Global, Kenya), Sergii Antoniak (Ukraine Center for Public Health), Linda Barlow-Mosha (Makerere University, Johns Hopkins University Research Collaboration, Uganda), Mark Boyd (University of Adelaide, Australia), Alexandra Calmy (Geneva University Hospital, Switzerland), Mohamed Chakroun (Monastir University Hospital, Tunisia), Martin Choo (Kuala Lumpur AIDS Support Services Society, Malaysia), Mark Cotton (Stellenbosch University, South Africa), Tendani Gaolathe (Ministry of Health, Botswana), Eric Goemaere (MSF, South Africa), Andreas Jahn (ITECH, Malawi), Nagalingeswaran Kumarasamy (YRGCARE Medical Centre, India), Thuy Le (Duke University, USA), Valeriane Leroy (Institut National de la Santé et de la Recherche Médicale, ANRS, France), Othoman Mellouk (ITPC, Morocco), Irene Mukui (Ministry of Health, Kenya), Angela Mushavi (Ministry of Health and Child Care, Zimbabwe), Landon Myer (University of Cape Town, South Africa), Thanyawee Puthanakit (Chulalong University, Bangkok, Thailand), Pablo Rojo (Complutense University of Madrid, Spain), Gayle Sherman (University of the Witwatersrand, South Africa), Wendy Stevens (NHLS and University of the Witwatersrand, South Africa), François Venter (University of the Witwatersrand, South Africa), and Annemarie Wensing (University Medical Centre of Utrecht, Netherlands).

Declarations of interest for members of the Guideline Development Group

Three members of the Guideline Development Group had conflicts of interest that excluded them from making decisions on recommendations for antiretroviral drug regimens. Web Annex A provides details of the management of conflicts of interest.

Representatives of United Nations agencies and other partners

Heather Alexander (United States Centers for Disease Control and Prevention, USA), Carolyn Amole (Clinton Health Access Initiative), Ava Avalos (Ministry of Health, Botswana), Carmen Perez Casas (Unitaid, Switzerland), Smiljka de Lussigny (Unitaid), Shaffiq Essajee (UNICEF), Ade Fakoya (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland), Peter Godfrey-Faussett (UNAIDS), Christine Malati (United States Agency for International Development), Elliot Piazas (United States Centers for Disease Control and Prevention, USA)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26072

